Position in CNTX
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$4,110,322
-$15,328,388 QoQ
Shares Held
7,419,355
0.0% QoQ
Ownership
8.08%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
#1
of 79 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CNTX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Deep Track Capital, LP holds $5,341,997,223 across 58 Biotechnology names. CNTX ranks #55 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IMVT |
Immunovant, Inc.
|
9,341,151 | $359,914,548 | |
| 2 | GPCR |
Structure Therapeutics Inc.
|
4,740,072 | $254,399,664 | |
| 3 | PCVX |
Vaxcyte, Inc.
|
4,300,000 | $249,959,000 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
825,000 | $248,349,750 | |
| 5 | MANE |
Veradermics, Inc
|
2,000,000 | $245,880,000 | |
| 6 | TARS |
Tarsus Pharmaceuticals, Inc.
|
3,666,768 | $230,786,377 | |
| 7 | OCUL |
Ocular Therapeutix, Inc
|
19,686,282 | $193,319,289 | |
| 8 | BMRN |
Biomarin Pharmaceutical Inc
|
3,307,481 | $189,254,062 |
All Filings in CNTX
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4,110,322 | 7,419,355 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $19,438,710 | 7,419,355 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $10,906,451 | 7,419,355 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $7,189,354 | 7,419,355 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $4,859,677 | 7,419,355 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $4,540,645 | 7,419,355 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $7,790,322 | 7,419,355 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $14,541,935 | 7,419,355 | Shares | Sole | 2024-11-14 | |
| 2024-06-30 | $14,875,806 | 7,419,355 | Shares | Sole | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||